KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity: 2009-2024

Historic Common Equity for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $732.8 million.

  • Acadia Pharmaceuticals' Common Equity rose 58.92% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 58.92%. This contributed to the annual value of $732.8 million for FY2024, which is 69.72% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Common Equity of $732.8 million as of FY2024, which was up 69.72% from $431.8 million recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Common Equity peaked at $732.8 million during FY2024, and registered a low of $400.4 million during FY2022.
  • Over the past 3 years, Acadia Pharmaceuticals' median Common Equity value was $431.8 million (recorded in 2023), while the average stood at $521.7 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Common Equity dropped by 25.97% in 2022 and then surged by 69.72% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Common Equity stood at $627.0 million in 2020, then decreased by 13.73% to $540.9 million in 2021, then declined by 25.97% to $400.4 million in 2022, then grew by 7.83% to $431.8 million in 2023, then skyrocketed by 69.72% to $732.8 million in 2024.